Literature DB >> 25957396

Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.

Rachel Thijssen1, Erik Slinger1, Katinka Weller2, Christian R Geest2, Tim Beaumont3, Marinus H J van Oers4, Arnon P Kater4, Eric Eldering5.   

Abstract

Entities:  

Keywords:  ABT-199; CD20 antibodies; chronic lymphocytic leukemia; kinase inhibitors; resistance

Mesh：

Substances：

Year:  2015        PMID： 25957396      PMCID： PMC5004430          DOI： 10.3324/haematol.2015.124560

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101.

Authors:  Margot Jak; Gregor G W van Bochove; Eric A Reits; Wouter W Kallemeijn; Jacqueline M Tromp; Pablo Umana; Christian Klein; Rene A W van Lier; Marinus H J van Oers; Eric Eldering
Journal:  Blood       Date:  2011-09-26       Impact factor: 22.113

2.  Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity.

Authors:  Laura A Smit; Delfine Y H Hallaert; René Spijker; Bart de Goeij; Annelieke Jaspers; Arnon P Kater; Marinus H J van Oers; Carel J M van Noesel; Eric Eldering
Journal:  Blood       Date:  2006-10-12       Impact factor: 22.113

3.  IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells.

Authors:  Maria Fernanda Pascutti; Margot Jak; Jacqueline M Tromp; Ingrid A M Derks; Ester B M Remmerswaal; Rachel Thijssen; Martijn H A van Attekum; Gregor G van Bochove; Dieuwertje M Luijks; Steven T Pals; René A W van Lier; Arnon P Kater; Marinus H J van Oers; Eric Eldering
Journal:  Blood       Date:  2013-09-06       Impact factor: 22.113

4.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

5.  Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.

Authors:  Jacqueline M Tromp; Christian R Geest; Esther C W Breij; Judith A Elias; Jacoline van Laar; Dieuwertje M Luijks; Arnon P Kater; Tim Beaumont; Marinus H J van Oers; Eric Eldering
Journal:  Clin Cancer Res       Date:  2011-11-29       Impact factor: 12.531

6.  Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma.

Authors:  Vicente Fresquet; Melissa Rieger; Carlo Carolis; Maria J García-Barchino; Jose A Martinez-Climent
Journal:  Blood       Date:  2014-04-30       Impact factor: 22.113

Review 7.  Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor.

Authors:  Elisa ten Hacken; Jan A Burger
Journal:  Clin Cancer Res       Date:  2013-12-09       Impact factor: 12.531

8.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

9.  Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.

Authors:  Meike Vogler; Michael Butterworth; Aneela Majid; Renata J Walewska; Xiao-Ming Sun; Martin J S Dyer; Gerald M Cohen
Journal:  Blood       Date:  2008-11-13       Impact factor: 22.113

10.  The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.

Authors:  Oliver Hantschel; Uwe Rix; Uwe Schmidt; Tilmann Bürckstümmer; Michael Kneidinger; Gregor Schütze; Jacques Colinge; Keiryn L Bennett; Wilfried Ellmeier; Peter Valent; Giulio Superti-Furga
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-07       Impact factor: 11.205
View more
  51 in total

1.  Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.

Authors:  Kevin J Freise; Aksana K Jones; Doerthe Eckert; Sven Mensing; Shekman L Wong; Rod A Humerickhouse; Walid M Awni; Ahmed Hamed Salem
Journal:  Clin Pharmacokinet       Date:  2017-05       Impact factor: 6.447

Review 2.  Cell Death Pathways in Lymphoid Malignancies.

Authors:  Luke Fletcher; Edward Nabrinsky; Tingting Liu; Alexey Danilov
Journal:  Curr Oncol Rep       Date:  2020-01-27       Impact factor: 5.075

3.  Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.

Authors:  Sigrid S Skånland; Anthony R Mato
Journal:  Blood Adv       Date:  2021-01-12

4.  The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1.

Authors:  M Larrayoz; S J Blakemore; R C Dobson; M D Blunt; M J J Rose-Zerilli; R Walewska; A Duncombe; D Oscier; K Koide; F Forconi; G Packham; M Yoshida; M S Cragg; J C Strefford; A J Steele
Journal:  Leukemia       Date:  2015-10-21       Impact factor: 11.528

Review 5.  Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.

Authors:  Joel D Leverson; Deepak Sampath; Andrew J Souers; Saul H Rosenberg; Wayne J Fairbrother; Martine Amiot; Marina Konopleva; Anthony Letai
Journal:  Cancer Discov       Date:  2017-11-16       Impact factor: 39.397

6.  Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL.

Authors:  Kallesh D Jayappa; Craig A Portell; Vicki L Gordon; Brian J Capaldo; Stefan Bekiranov; Mark J Axelrod; L Kyle Brett; Julia D Wulfkuhle; Rosa I Gallagher; Emanuel F Petricoin; Timothy P Bender; Michael E Williams; Michael J Weber
Journal:  Blood Adv       Date:  2017-06-13

Review 7.  Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies.

Authors:  Steven Grant
Journal:  Leuk Lymphoma       Date:  2017-08-24

Review 8.  The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia.

Authors:  Gilad Itchaki; Jennifer R Brown
Journal:  Ther Adv Hematol       Date:  2016-07-08

9.  The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.

Authors:  Matthew D Blunt; Stefan Koehrer; Rachel C Dobson; Marta Larrayoz; Sarah Wilmore; Alice Hayman; Jack Parnell; Lindsay D Smith; Andrew Davies; Peter W M Johnson; Pamela B Conley; Anjali Pandey; Jonathan C Strefford; Freda K Stevenson; Graham Packham; Francesco Forconi; Greg P Coffey; Jan A Burger; Andrew J Steele
Journal:  Clin Cancer Res       Date:  2016-10-03       Impact factor: 12.531

10.  Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.

Authors:  Elisa Ten Hacken; Rebecca Valentin; Fara Faye D Regis; Jing Sun; Shanye Yin; Lillian Werner; Jing Deng; Michaela Gruber; Jessica Wong; Mei Zheng; Amy L Gill; Michael Seiler; Peter Smith; Michael Thomas; Silvia Buonamici; Emanuela M Ghia; Ekaterina Kim; Laura Z Rassenti; Jan A Burger; Thomas J Kipps; Matthew L Meyerson; Pavan Bachireddy; Lili Wang; Robin Reed; Donna Neuberg; Ruben D Carrasco; Angela N Brooks; Anthony Letai; Matthew S Davids; Catherine J Wu
Journal:  JCI Insight       Date:  2018-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.